Posted on December 17, 2019 by Sitemaster
Yesterday the U.S. Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of metastatic, hormone-sensitive prostate cancer (mHSPC) — also known as metastatic, castration-rsensitive prostate cancer or mCSPC. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: enzalutamide, hormone-sensitive, HSPC, metastatic, Xtandi | 3 Comments »
Posted on February 15, 2019 by Sitemaster
On Thursday, here in San Francisco, Dr. Andrew Armstrong first presented the results of the so-called ARCHES trial of enzalutamide (Xtandi) + standard androgen deprivation therapy (ADT) in the treatment of men with metastatic, “hormone-sensitive” prostate cancer (mHSPC). … READ MORE …
Filed under: Uncategorized | Tagged: ADT, ARCHES, enzalutamide, hormone-sensitive, metastatic, mHSPC, Xtandi | 4 Comments »
Posted on September 28, 2016 by Sitemaster
As of midnight last night, Pfizer completed the acquisition of Medivation and therefore enzalutamide (Xtandi) is now being sold in the USA by Pfizer and Astellas and by Astellas in the rest of the world. For the details, see here.
Filed under: Uncategorized | Tagged: enzalutamide, Medivation, Pfizer, Xtandi | 1 Comment »
Posted on August 22, 2016 by Sitemaster
According to news this morning, Pfizer has entered into a merger agreement which will allow the company to buy Medivation (the developer of enzalutamide, also known as Xtandi). Rumors had been rife since last Friday. … READ MORE …
Filed under: Uncategorized | Tagged: enzalutamide, Xtandi | 1 Comment »
Posted on March 30, 2016 by Sitemaster
According to a story on the MarketWatch web site yesterday, two not-for-profit organizations have been seeking hearings on revocation of patents held by Medivation on the drug enzalutamide (Xtandi). … READ MORE …
Filed under: Uncategorized | Tagged: cost, enzalutamide, hearing, price, Xtandi | 11 Comments »
Posted on December 11, 2015 by Sitemaster
According to an article this morning on the PharmaTimes web site, Astellas has convinced the National Institute for Health and Care Excellence (NICE) to recommend coverage of enzalutamide (Xandi) in chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Treatment | Tagged: abiraterone, coverage, enzalutamide, NICE, UK, Xtandi, Zytiga | 3 Comments »
Posted on April 1, 2013 by Sitemaster
According to a media release issued by Astellas Pharma and Medivation, the companies now expect to conduct an interim analysis of the PREVAIL trial of enzalutamide (a.k.a. MDV3100 or Xtandi) for overall survival some time later this year. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, chemotherapy-naïve, enzalutamide, mCRPC, metastatic, PREVAIL, Xtandi | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 